Advertisement
Screener

MiMedx Group, Inc. (MDXG) Net Income (Loss) Available to Common Stockholders, Basic

2.8 / 5 stars · 68/120 Roast Me

MiMedx Group, Inc. Net Income (Loss) Available to Common Stockholders, Basic

MiMedx Group, Inc. (MDXG) reported Net Income (Loss) Available to Common Stockholders, Basic of $6.76 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-10-30.

Discontinued › Income Statement › Net Income

us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2023-10-30

  • MiMedx Group, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-09-30 was $6.76M.
  • MiMedx Group, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-06-30 was -$528.00K.
  • MiMedx Group, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-03-31 was -$6.67M.
  • MiMedx Group, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2022-12-31 was -$2.11M, a 441.42% decline year-over-year.
  • MiMedx Group, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$36.78M.
  • MiMedx Group, Inc. net income (loss) available to common stockholders, basic for fiscal 2021 was -$16.42M.
  • MiMedx Group, Inc. net income (loss) available to common stockholders, basic for fiscal 2020 was -$83.33M.
  • MiMedx Group, Inc. net income (loss) available to common stockholders, basic for fiscal 2019 was -$25.58M.
Period endNet Income (Loss) Available to Common Stockholders, Basic 3 monthNet Income (Loss) Available to Common Stockholders, Basic 6 monthNet Income (Loss) Available to Common Stockholders, Basic 9 monthNet Income (Loss) Available to Common Stockholders, Basic 12 month
2023-09-30$6.76M
10-Q · filed 2023-10-30
$6.23M
derived: sum of 2 quarters · filed 2023-10-30
-$433.00K
10-Q · filed 2023-10-30
-$2.54M
derived: sum of 4 quarters · filed 2023-10-30
2023-06-30-$528.00K
10-Q · filed 2023-08-01
-$7.19M
10-Q · filed 2023-08-01
-$9.30M
derived: sum of 3 quarters · filed 2023-08-01
-$19.40M
derived: sum of 4 quarters · filed 2023-10-30
2023-03-31-$6.67M
10-Q · filed 2023-05-02
-$8.78M
derived: sum of 2 quarters · filed 2023-05-02
-$18.87M
derived: sum of 3 quarters · filed 2023-10-30
-$31.37M
derived: sum of 4 quarters · filed 2023-10-30
2022-12-31-$2.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
-$12.21M
derived: sum of 2 quarters · filed 2023-10-30
-$24.70M
derived: sum of 3 quarters · filed 2023-10-30
-$36.78M
10-K · filed 2023-02-28
2022-09-30-$10.10M
10-Q · filed 2023-10-30
-$22.59M
derived: sum of 2 quarters · filed 2023-10-30
-$34.67M
10-Q · filed 2023-10-30
-$34.05M
derived: sum of 4 quarters · filed 2023-10-30
2022-06-30-$12.50M
10-Q · filed 2023-08-01
-$24.57M
10-Q · filed 2023-08-01
-$23.95M
derived: sum of 3 quarters · filed 2023-08-01
-$27.87M
derived: sum of 4 quarters · filed 2023-08-01
2022-03-31-$12.07M
10-Q · filed 2023-05-02
-$11.46M
derived: sum of 2 quarters · filed 2023-05-02
-$15.37M
derived: sum of 3 quarters · filed 2023-05-02
-$18.65M
derived: sum of 4 quarters · filed 2023-05-02
2021-12-31$618.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
-$3.29M
derived: sum of 2 quarters · filed 2023-02-28
-$6.57M
derived: sum of 3 quarters · filed 2023-02-28
-$16.42M
10-K · filed 2023-02-28
2021-09-30-$3.91M
10-Q · filed 2022-11-02
-$7.19M
derived: sum of 2 quarters · filed 2022-11-02
-$17.04M
10-Q · filed 2022-11-02
-$35.10M
derived: sum of 4 quarters · filed 2023-02-28
2021-06-30-$3.28M
10-Q · filed 2022-08-02
-$13.13M
10-Q · filed 2022-08-02
-$31.18M
derived: sum of 3 quarters · filed 2023-02-28
-$83.17M
derived: sum of 4 quarters · filed 2023-02-28
2021-03-31-$9.85M
10-Q · filed 2022-05-03
-$27.91M
derived: sum of 2 quarters · filed 2023-02-28
-$79.89M
derived: sum of 3 quarters · filed 2023-02-28
-$88.36M
derived: sum of 4 quarters · filed 2023-02-28
2020-12-31-$18.06M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
-$70.04M
derived: sum of 2 quarters · filed 2023-02-28
-$78.51M
derived: sum of 3 quarters · filed 2023-02-28
-$83.33M
10-K · filed 2023-02-28
2020-09-30-$51.98M
10-Q · filed 2021-11-02
-$60.45M
derived: sum of 2 quarters · filed 2021-11-02
-$65.27M
10-Q · filed 2021-11-02
-$72.75M
derived: sum of 4 quarters · filed 2022-02-28
2020-06-30-$8.47M
10-Q · filed 2021-08-03
-$13.29M
10-Q · filed 2021-08-03
-$20.76M
derived: sum of 3 quarters · filed 2022-02-28
-$8.38M
derived: sum of 4 quarters · filed 2022-02-28
2020-03-31-$4.82M
10-Q · filed 2021-04-28
-$12.30M
derived: sum of 2 quarters · filed 2022-02-28
$82.00K
derived: sum of 3 quarters · filed 2022-02-28
2019-12-31-$7.48M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
$4.90M
derived: sum of 2 quarters · filed 2022-02-28
-$25.58M
10-K · filed 2022-02-28
2019-09-30$12.38M
10-Q · filed 2020-11-04
-$18.10M
10-Q · filed 2020-11-04
2018-12-31-$29.98M
10-K · filed 2021-03-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
ANGIODYNAMICS INC (ANGO)United States$0.632B-13.02
ORTHOPEDIATRICS CORP (KIDS)United States$0.592B
SS Innovations International, Inc. (SSII)$0.589B-64.06
DELCATH SYSTEMS, INC. (DCTH)United States$0.558B820.33
SI-BONE, Inc. (SIBN)United States$0.830B-49.82
CERUS CORP (CERS)United States$0.525B-86.40
TACTILE SYSTEMS TECHNOLOGY INC (TCMD)United States$0.519B27.16
NeuroPace Inc (NPCE)United States$0.480B-28.52
Sight Sciences, Inc. (SGHT)United States$0.478B-9.95
SpyGlass Pharma, Inc. (SGP)United States$0.925B